France's Cellectis wins U.S patents for gene editing technology

loading...


France’s Cellectis wins U.S patents for gene editing technology
PARIS (Reuters) – The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.


Source: Health And Fitness

Reply

Pin It on Pinterest

Shares
Share This
loading...